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Orphan drug developmentFriedreich ataxia is an inherited neurodegenerative disease that leads to progressive disability. There is currently
no effective treatment and patients die prematurely. The underlying genetic defect leads to reduced expression of
the mitochondrial protein frataxin. Frataxin insufﬁciency causes mitochondrial dysfunction and ultimately cell
death, particularly in peripheral sensory ganglia. There is an inverse correlation between the amount of residual
frataxin and the severity of disease progression; therefore, therapeutic approaches aiming at increasing frataxin
levels are expected to improve patients' conditions. We previously discovered that a signiﬁcant amount of
frataxin precursor is degraded by the ubiquitin/proteasome system before its functional mitochondrial matura-
tion. We also provided evidence for the therapeutic potential of small molecules that increase frataxin levels
by docking on the frataxin ubiquitination site, thus preventing frataxin ubiquitination and degradation.We called
these compounds ubiquitin-competing molecules (UCM). By extending our search for effective UCM, we identi-
ﬁed a set of new and more potent compounds that more efﬁciently promote frataxin accumulation. Here we
show that these compounds directly interact with frataxin and prevent its ubiquitination. Interestingly, these
UCM are not effective on the ubiquitin-resistant frataxin mutant, indicating their speciﬁc action on preventing
frataxin ubiquitination. Most importantly, these compounds are able to promote frataxin accumulation and
aconitase rescue in cells derived from patients, strongly supporting their therapeutic potential.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Friedreich ataxia (FRDA) is a genetic neurodegenerative disease that
affects children and young adults and leads to progressive disability and
premature death (Pandolfo and Pastore, 2009). It has an autosomal re-
cessive inheritance with an estimated prevalence of 1:50,000 in the
Caucasian population, thus representing the most common form of
inherited ataxia. Characteristic symptoms include progressive loss of
movement coordination, gait instability, muscle weakness and sensory
loss. Symptoms usually appear around puberty and patients usually
require wheelchairs within 10 to 15 years from disease onset. Disease
progression is often associated with loss of visual acuity, slurred speechsduction, University of Rome
ect.com).
. This is an open access article underand dysphagia. Neurological signs are associated with degeneration of
sensory neurons in the dorsal root ganglia and dentate nucleus of the
cerebellum.Moreover, patients often develop a hypertrophic cardiomy-
opathy that is often the cause of premature death (Weidemann et al.,
2013). A signiﬁcantly higher incidence of diabetes mellitus is also asso-
ciated with the disease, with more than 25% of patients developing glu-
cose intolerance or diabetes (Cnop et al., 2013). The disease is caused by
a GAA triplet-repeat expansionwithin the ﬁrst intron of the gene coding
for frataxin (Campuzano et al., 1996), which results in reduced tran-
scription of the gene. The vast majority of patients present a homozy-
gous repeat expansion on both alleles, while about 4% of patients
present a GAA repeat expansion on one allele and a point mutation in
the coding region on the other allele. In normal individuals the number
of GAA triplets range between 10 and 35, while in affected individuals
GAA triplets range from 66 up to more than 1700 (Yandim et al.,
2013). This is associated with a number of epigenetic changes that
lead to heterochromatinization of this portion of DNA and impairmentthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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formation of an atypical “sticky” triple DNA structure has also been
found associated with the expanded GAA triplet, also accounting for
the observed gene silencing (Bidichandani et al., 1998; Sakamoto
et al., 2001). The genetic defect results in a severely reduced transcrip-
tion of the frataxin gene, with patients living with residual 10-30%
frataxin (Yandim et al., 2013).
Frataxin is a highly conserved mitochondrial protein (Pastore and
Puccio, 2013), synthesized in the cytosol as a precursor form, which is
then processed by a mitochondrial processing peptidase in a two-step
catalytic process, and concomitantly imported into mitochondria
(Koutnikova et al., 1998). The functional mature form is a 130 amino
acid polypeptide (Condò et al., 2007), mainly located within the mito-
chondrial matrix. Frataxin is involved in iron metabolism and partici-
pates in the biogenesis of iron-sulfur clusters (ISC) (Vaubel and Isaya,
2013). It is therefore essential for the enzymatic activity of complex I,
II and III of the mitochondrial respiratory chain and of aconitases
(Bulteau et al., 2004; Condò et al., 2010; Rotig et al., 1997), which re-
quire ISC as cofactors. Therefore, frataxin-deﬁcient cells present an im-
pairment in the electron transport chain and inefﬁcient mitochondrial
respiration. Iron distribution is consequently affected in frataxin-
deﬁcient cells, resulting in intramitochondrial iron overload (Martelli
and Puccio, 2014). As a result of dysregulated mitochondrial metabo-
lism, frataxin-deﬁcient cells have reduced ATP content and increased
ROS generation. Moreover, frataxin insufﬁciency results in impaired in-
tracellular anti-oxidant defenses (Paupe et al., 2009; Shan et al., 2013).
To date, no effective therapy has been approved to treat FRDA.
Frataxin insufﬁciency is considered the main pathogenic cause of the
disease and a correlation exists between the length of the GAA expan-
sion and the extent of transcription impairment. Moreover, the amount
of residual frataxin has been correlated to the age at disease onset and to
the severity of disease progression (Parkinson et al., 2013). Since the
coding sequence of frataxin is unaltered in patients, therapeutic ap-
proaches aiming at increasing frataxin levels (Herman et al., 2006;
Marmolino et al., 2009; Tomassini et al., 2012) are therefore expected
to ameliorate disease symptoms and to slow down disease progression.
Both promoting frataxin gene expression and preventing frataxin pro-
tein degradation can in principle lead to an increase in frataxin levels.
We recently focused our studies on the therapeutic potential of
preventing frataxin degradation to promote its accumulation.
We have previously shown that frataxin levels are controlled by the
ubiquitin/proteasome system (UPS) and that frataxin can be directly
modiﬁed by ubiquitin (Ruﬁni et al., 2011). The UPS is the most impor-
tant and widely studied system for intracellular protein degradation.
Lysine residues on the protein substrate are recognized by speciﬁc
enzymes and modiﬁed by the covalent attachment of one or more
ubiquitin moieties. This event marks the protein for degradation in the
proteasome (Glickman and Ciechanover, 2002). We identiﬁed the criti-
cal lysine on frataxin, lysine 147 (K147), which is the main target of
ubiquitination. This lysine represents a crucial site for frataxin stability.
Indeed a frataxin mutant that lacks this lysine cannot be ubiquitinated
and is more stable. Therefore, preventing ubiquitination on K147 is ex-
pected to grant frataxin an increased stability and a prolonged half-life.
Indeed, from computational docking studies, we identiﬁed a set of small
molecules, predicted to interact with themolecular pocket surrounding
K147, able to interfere with frataxin ubiquitination and promote
frataxin accumulation in cells derived from patients. Moreover, these
molecules, named ubiquitin-competingmolecules (UCM), can promote
a functional rescue of mitochondrial dysfunction caused by frataxin de-
ﬁciency in patients cells (Ruﬁni et al., 2011).
We have now extended our search to ﬁnd more effective com-
pounds. We show here that these “second-generation” UCM, physically
interact with frataxin and prevent its ubiquitination. Moreover, these
compounds can increase frataxin levels in cells overexpressing frataxin,
but not in cells overexpressing the ubiquitin-resistant K147R frataxin
mutant, suggesting that they act by inhibiting ubiquitination on K147.Importantly, they show efﬁcacy in promoting accumulation of mature
frataxin, and in restoring aconitase activity in cells derived from
patients, strongly supporting their potential therapeutic application.
Results
Computational screening for ubiquitin-competing molecules (UCM)
In order to design small molecules able to inhibit the ubiquitination
of frataxin, an extended analysis of the protein's accessible surfaces has
been performed, extending our previous work, by taking into account
protein ﬂexibility. This analysis allowed us to identify binding pockets
on frataxin that were more accessible to drugs. By focusing our analysis
on the areas more proximal to K147, and by using virtual screening of
commercially available compound libraries, several thousand com-
pounds were docked on available NMR and x-ray structures of human
frataxin. Some of these molecules were predicted to interact with
frataxin near to K147 (Fig. 1). Promising candidates were subjected to
functional validation.
UCM increase frataxin levels
To validate UCM activity, we tested their effect in human HEK-293
cells stably expressing single copy frataxin (293-frataxin). These cells
allow the detection of all forms of frataxin, including the frataxin pre-
cursor. Compounds that were able to enhance frataxin precursor levels
were further chemically modiﬁed to better ﬁt the docking model, syn-
thesized and tested again in 293-frataxin. This process was repeated
in an iterative cycle with the aim to improve the efﬁcacy of the UCM.
Approximately 200 new candidate UCM were tested in functional as-
says. Through this process, we were able to identify new UCM that pro-
mote frataxin precursor accumulation more efﬁciently than the
previously described compounds. Structures of the compounds de-
scribed in this study are shown in Table 1. Indeed, the treatment of
293-frataxin cellswith 10 μMUCM53, UCM108 andUCM71 is able to in-
duce frataxin precursor accumulation (Fig. 2A) more efﬁciently than
with the previously described UCM2 (referred to as NSC620301 in
(Ruﬁni et al., 2011)) or with the proteasome inihibitor MG132.
Importantly, an accumulation of mature frataxin can also be observed
in these cells when treatment is prolonged for 3 days (Fig. 2B).
UCM prevent frataxin ubiquitination
To test whether the new compounds promote frataxin accumulation
by preventing its UPS-dependent degradation, we evaluated their impact
on frataxin ubiquitination. To this aim, we performed an in vivo
ubiquitination assay. HEK-293 cells were transiently co-transfected with
hemagglutinin-tagged ubiquitin (HA-Ub) and frataxin, in the presence
of proteasome inhibitor and deubiquitinase inhibitor to allow the accu-
mulation of ubiquitinated species, in the presence of the selected com-
pounds. The ubiquitination status of frataxin was evaluated by SDS–
PAGE of total cell lysates and anti-frataxin immunoblotting. As previously
described, in this experimental setting, frataxin monoubiquitinated
forms can be detected by anti-frataxin antibody as a slower migrating
band above frataxin precursor (Ruﬁni et al., 2011). Ubiquitination
level was measured as the ratio between the levels of ubiquitinated
frataxin and frataxin precursor. As shown in Fig. 3, UCM53 and
UCM71 but not the control non-effective molecule UCM57, can signiﬁ-
cantly abrogate frataxin ubiquitination. These data suggest that the se-
lected UCM interfere with frataxin ubiquitination in living cells.
UCM promote frataxin accumulation by preventing K147-dependent
degradation
Wehad previously shown that K147 is the crucial ubiquitination site
on frataxin. Since we showed that these compounds are able to
Fig. 1. Docking model of UCM71 to frataxin. (A) Crystal structure of frataxin (gray cartoon) with solvent accessible molecular surface around the W155 pocket. Overall structure as grey
cartoon, molecular surface colored by lipophilicity (hydrophilic in magenta, lipophilic in green). (B) Putative model of the interaction betweenW155 pocket and the ligand UCM71 (ball
and stick, CPK colors): the solvent accessible ligand surface (light bluemesh) ﬁts perfectly with the naphthyl moiety buried byW155, P163, and S157. The phenothiazine ring recognizes
theﬂat region formedbyN146 andK147 (label not shown for clarity) and delimited by side chains of V131, S129, T149 andQ148. (C) Putative selected interactions of UCM71with frataxin.
Hydrogen bonds are formed between the hydroxyl substituent of the naphthyl group and the side chain of N146 and between the carbonyl group of the carbonyl-hydrazone scaffold and
the hydroxyl of S157. These interactions induceminor rearrangements in the involved side chains of N146 (ﬂip of terminal amide) and S157. (D) The ﬂexibility of the carbonyl-hydrazone
scaffold permits theﬂip of phenothiazinemoiety to point its central amino group toward Q148 possibly inducing the ﬂip of the amide group of its side chain resulting in the formation of a
strong hydrogen bond.
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they act by interfering with ubiquitination on K147. Thus, to validate
this hypothesis, we evaluated their effect on the frataxin mutant
that lacks K147 (K147R). This mutant cannot be ubiquitinated and is
therefore resistant to UPS-mediated degradation. Small molecules
that act by preventing ubiquitination on K147 are expected to be inef-
fective on this mutant. We therefore tested their effect on HEK-293
cells stably expressing the ubiquitin-refractory frataxinK147R mutant
(293-frataxinK147R). Cells were treated for 24 h with the indicated com-
pounds and frataxin precursor levels analyzed by western blot on total
cell extract. Indeed, we could show that when 293-frataxinK147R are
treated with the selected UCM, no signiﬁcant increase in frataxin pre-
cursor levels can be detected (Fig. 4), compared to what observed in
293-frataxin, expressing wild-type frataxin. These data suggest that
UCM act on frataxin by interfering with the K147-dependent degrada-
tion pathway.UCM interact with frataxin
Ubiquitin-competing molecules were selected through structure-
based virtual screening for their potential ability to interact with
frataxin on its ubiquitination site. Since they are in fact able to prevent
frataxin ubiquitination and to interfere with its K147-dependent degra-
dation, we wanted to conﬁrm their ability to physically interact with
frataxin. Therefore, the interaction propensities of frataxin with these
molecules were investigated by ﬂuorescence spectroscopy through
the analysis of the changes of the signal of the protein tryptophan
residues in the presence of the different compounds. In Fig. 5, we have
reported the binding isotherm of the protein to four different com-
pounds, UCM53 and UCM108 that promote frataxin accumulation, and
UCM72 and UCM57 that are unable to promote frataxin accumulation
(see below), as a control. One of the effective compounds (UCM53)
was also exposed to the denatured protein. The half-saturation binding
Table 1
Chemical structure and activity of the compounds described in the present study.
Compound name Structure Activity
UCM53 +
UCM57 −
UCM71 +
UCM72 −
UCM108 +
Fig. 3. UCM prevent frataxin ubiquitination. (A) 293 cells were transiently co-transfected
with HA-Ub and frataxin1-210. Twenty-four hours after transfection, cells were treated
with 10 μM of the indicated UCM or with DMSO alone (contr). UCM57 was used as a
non-effective control molecule. Cells were harvested 48 h after transfection. Where indi-
cated (MG), cells were also treated with 10 μMMG132 and 50 ng/ml ubiquitin-aldehyde
for the last 16 h. Total cell extracts were resolved on SDS–PAGE and revealed with anti-
frataxin antibody. The arrows indicate the bands corresponding to frataxin precursor
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responding panel. UCM53 and UCM108 showed strong ﬂuorescence
changes (left panels) and the lowest binding constants, while the con-
trol UCM72 showed the highest binding constant (upper right panel).
Fluorescent changes induced by UCM53 were completely lost using
the denatured protein (upper left panel, black square symbols). The in-
teraction of frataxin with the control molecule UMC57 was also studiedFig. 2. UCM increase frataxin levels. (A) To detect frataxin precursor accumulation, 293
Flp-In cells stably expressing frataxin1-210 were treated for 24 hrs with 10 μM of the indi-
catedUCM or 10 μMMG132 (MG). Total cell extracts were resolved on SDS–PAGE and an-
alyzed with anti-frataxin antibody, or anti-tubulin, as a loading control. Pre: precursor;
tub: tubulin. (B) To detectmature frataxin accumulation, 293 Flp-In cells stably expressing
frataxin1-210 were treated for 72 hrs with 10 μM of the indicated UCM. Total cell extracts
were resolved on SDS–PAGE and analyzed with anti-frataxin antibody, or anti-tubulin,
as a loading control. Pre: precursor, int: intermediate, mat: mature; tub: tubulin.
(Fxn-pre) and ubiquitin-conjugated frataxin (Ub-Fxn). (B) The graph represents the rela-
tive ubiquitination levels, quantiﬁed as the densitometric ratio between ubiquitinated
frataxin bands and frataxin precursor bands for each MG132-treated lanes. Data represent
the mean ± SEM from ﬁve different independent experiments. P-values were calculated
with Student's t-test andwere statistically signiﬁcant (**P b 0.01) compared to non-treated
control.by ﬂuorescence (lower right panel). In this case, the spectroscopic
properties of the protein do not signiﬁcantly change in the presence
of this compound obtaining similar results to those of denatured
protein + UCM53 (upper left panel, black squares). These results indi-
cate that UCM53 and UCM108 strongly interact with tryptophans likely
due to a quite efﬁcient binding.
UCMpromote frataxin accumulation in FRDA cells and rescue the aconitase
defect
We ﬁnally analyzed the efﬁcacy of our compounds in cells derived
from FRDA patients. Lymphoblast cell lines derived from two different
patients, FRDA 798 and FRDA 214 were cultured for 5 days in the pres-
ence of 10 μM of UCM53 or UCM108, the two most promising com-
pounds. UCM71 could not be evaluated because of its toxicity over a
long-term treatment (Fig. S1). Frataxin levels were quantiﬁed by west-
ern blot analysis onwhole cell extracts. Importantly, we could observe a
signiﬁcant accumulation of mature frataxin when cells are cultured in
the presence of UCM53 or UCM108, compared to cells treated with ve-
hicle alone (control), or UCM72 (Figs. 6A and B). Frataxin levels in treat-
ed cells derived from patients are also compared to the levels observed
in cells derived from unaffected carrier siblings (FRDA 241 and FRDA
215). These UCM are also more effective than the previously described
compounds (Ruﬁni et al., 2011). Indeed, at the concentration of 10 μM
that is efﬁcacious for the newUCM, the previously described compound
does not show a signiﬁcant effect (Fig. S2).Moreover, to validate a func-
tional recovery of frataxin levels, rescue of cellular aconitases activity
was evaluated in FRDA cells upon treatment with UCM. A signiﬁcant
increase in aconitases activity was observed in patient-derived
Fig. 4. UCM promote frataxin precursor accumulation by preventing K147-dependent
degradation. (A) 293 Flp-In cells stably expressing frataxin1-210 (293-frataxin) or the
lysine-mutant frataxinK147R (293-frataxinK147R) were treated for 24 hrs with 10 μM of
the indicated UCM. Proteins were resolved on SDS–PAGE and revealed with anti-frataxin
antibody or anti-tubulin, as a loading control. Pre: precursor; tub: tubulin. (B) The graph
represents relative frataxin precursor levels as quantiﬁed by densitometric analysis. Data
represent the mean ± SEM from ﬁve different independent experiments. P-values were
calculated with Student's t-test and were statistically signiﬁcant (*P b 0.05; **P b 0.01).
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(Fig. 6C). Aconitases activity in cells derived from an unaffected carrier
sibling (FRDA 215) is also shown for comparison. Thus, importantly,
these data indicate that treatment with UCM allows accumulation of a
functional form of mature frataxin with consequent reactivation of ISC
biogenesis.
Discussion
The present study supports the potential role of smallmolecules that
prevent frataxin ubiquitin-dependent degradation as a novel therapeu-
tic strategy to treat FRDA. There is currently no approved therapy for
FRDA and only limited treatment for the management of symptoms
are available for patients (Delatycki, 2009; Schulz et al., 2009). Since pa-
tients lack a sufﬁcient amount of mitochondrial frataxin, increasing the
amount of frataxin is themain therapeutic goal (Perdomini et al., 2014).
We had previously shown (Ruﬁni et al., 2011) that a signiﬁcant portion
of the frataxin precursor is degraded by the UPS before it reaches the
mitochondria, where it undergoes maturation and becomes functional.
We therefore reasoned that preventing frataxin precursor degradation
could lead to an increase in the pool of frataxin available for mitochon-
drial import. Importantly, we had previously provided evidence for
the therapeutic potential of small molecules that prevent frataxin
ubiquitination by docking to the frataxin ubiquitination site (Ruﬁni
et al., 2011). We now extended our search to identify more effective
compounds showing increased afﬁnity toward frataxin and improved
efﬁcacy in cells derived from patients. Moreover, we provide important
insight into the mechanism of action of these compounds. Indeed, the
fact that these molecules are not effective in cells expressingfrataxinK147R, a frataxin mutant lacking the critical ubiquitination site,
strongly supports their predicted role in preventing ubiquitination on
that particular lysine residue. In line with these data, we provide for
the ﬁrst time evidence for the direct binding of these compounds with
frataxin. Indeed, ﬂuorescence spectroscopy experiments indicate that
selected compounds can physically interact with frataxin in vitro, as pre-
dicted by the in silico studies. Importantly, we could show that the activ-
ity of aconitase that strongly depends on frataxin is partially rescued
upon treatmentwithUCM in cells derived frompatients. These data sug-
gest that interaction with UCM does not alter frataxin function. One of
the compounds described in this paper, UCM71, however shows some
toxic effect on cell viability andwas therefore not considered for further
studies. Further insight into the binding mode of these UCM to frataxin
will be helpful for the future development of the identiﬁed leads and
will guide the design of new derivatives with improved efﬁcacy.
The function of the UPS is critical for the regulation of protein turn-
over and the maintenance of protein homeostasis. The stability of
many intracellular targets is known to be altered in a number of dis-
eases, including cancer and neurodegenerative disorders. Given the im-
portance of the UPS in controlling protein stability and degradation,
many components of the system represent important therapeutic tar-
gets (Bedford et al., 2011; Shen et al., 2013; Zhang and Sidhu, 2014).
Several small molecule inhibitors that target different steps of the
ubiquitination and degradation pathway have been developed. Among
those, two proteasome inhibitors, Bortezomib and Carﬁlzomib, are
now approved for cancer treatment (Kisselev et al., 2012; Rentsch
et al., 2013; Richardson et al., 2006). However, targeting the proteasome
as a whole is too unspeciﬁc and may result in many undesired out-
comes. The identiﬁcation of new and more speciﬁc therapeutic targets
among UPS components is crucial for the design of more selective
therapies. E3 ligases are the enzymes responsible for substrate recogni-
tion and confer speciﬁcity to the ubiquitination process. They therefore
represent attractive and more selective pharmacological targets. A
widely studied example in the ﬁeld is the ubiquitination of p53 by its
E3 ligase HDM2 (Kussie et al., 1996). Different strategies have been
adopted to prevent p53 ubiquitination. A number of small molecule
inhibitors have been developed that prevent p53/HDM2 interaction,
either by binding to the p53-binding pocket on HDM2, like Nutlin3
(Vassilev et al., 2004) or MI-63 (Ding et al., 2006), or by inducing a con-
formational change on p53, like RITA (Issaeva et al., 2004). Alternatively,
other compounds, like HLI98, directly bind to the HDM2 catalytic pock-
et, thus inhibiting its enzymatic activity (Roxburgh et al., 2012; Yang
et al., 2005). Other small molecule inhibitors have been developed
that target the activity of multi-subunit E3 ligase complexes, like the
Cullin family of RING E3 ligases, which are responsible for the
ubiquitination of a large number of intracellular substrates. MLN4924
prevents the neddylation of Cullins, a step required for their activation,
thereby preventing the degradation of all Cullin substrates (Brownell
et al., 2010; Soucy et al., 2009). Other compounds interfere with the as-
sembly of themulti-subunit complex (Chen et al., 2008) or directly pre-
vent interaction of the adaptor subunit with the substrate (Wu et al.,
2012). However, to our knowledge, our therapeutic strategy represents
theﬁrst example of a smallmolecule inhibitor developed todirectly target
ubiquitination site on the substrate protein to prevent its degradation.
This approach could potentially be applied to prevent ubiquitination of
other crucial intracellular substrates. As an alternative and complementa-
ry approach to prevent frataxin degradation, we are now pursuing the
identiﬁcation of the frataxin-speciﬁc E3 ligase, which will represent an-
other attractive therapeutic target to treat FRDA.
Methods
Cell culture and transfections
Human embryonic kidney HEK-293 cells were cultured in Dulbecco's
modiﬁed Eagle's medium (DMEM) supplemented with 10% fetal bovine
Fig. 5. UCM interact with frataxin. Fluorescence studies of the interaction of 2 μM recombinant frataxin precursor with different concentration of the indicated UCM (ligand). The graphs
represent the fractional loss of the protein ﬂuorescence intensity (ΔF/F0), in the presence of different concentration of ligand, versus the ratio between ligand and frataxin. The interaction
with UCM53 was also analyzed in the case of frataxin precursor previously denaturated in 3 M guanidinium hydrochloride (upper left panel, black square symbols). The half-saturation
binding constant, L1/2 (μM), of frataxin precursor with UCM53, UCM108 and UCM72 is indicated in each corresponding panel.
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reagents (Invitrogen), according to the manufacturer's instructions. Cells
were plated on 6 cm dishes and transfected with 8 μg of total DNA (4 μg
of pIRES-frataxin and 4 μg of HA-Ub). The day after transfection, cells
were treated for 24 h with 10 μMUCM together with 10 μM proteasome
inhibitor MG132 and 50 ng/ml deubiquitinating enzyme (DUB) inhibitor
Ub-aldehyde. HEK-293 Flp-In cells (Invitrogen) are HEK-293 variants
allowing the stable and isogenic integration and expression of a
transfected gene. The HEK-293 clones stably expressing frataxin1–210 or
frataxinK147R were previously described (Condò et al., 2007; Ruﬁni et al.,
2011). FRDA 214 (GM16214) and FRDA 798 (GM16798) lymphoblasts,
from clinically affected FRDA patients, as well as FRDA 215 (GM16215)
and FRDA241 (GM16241) lymphoblasts, from the correspondent hetero-
zygous clinically unaffected sibling, were obtained from Coriell Cell
Repositories (Camden,NJ, USA) andwere cultured in RPMI supplemented
with 15% FBS.Antibodies
The following antibodies were used for Western Blot analysis: mAb
anti-frataxin (MAB-10876, Immunological Sciences), mAb anti-tubulin
(Sigma-Aldrich) and secondary antibody horseradish peroxidase-
conjugated goat anti-mouse (Pierce).Chemicals
Proteasome inhibitors: MG132 (Sigma-Aldrich); DUB inhibitors:
Ub-aldehyde (Biomol) and N-ethylmaleimide (NEM; Sigma-Aldrich).
UCM were obtained from Enamine or were synthesized. The identity
and purity of the compounds obtainedwere determined by TLC analysis
and 1H-NMR.DNA constructs
The pIRES2–frataxin1–210 and pIRES2-frataxinK147R constructs were
previously described (Condò et al., 2006; Ruﬁni et al., 2011). The HA-
Ub construct was generated by M. Treier in Dirk Bohmann's lab
(Treier et al., 1994).
Immunoblotting
Total cell extractswere prepared in IP buffer (50mMTris–HCl, pH 7.5,
150mMNaCl, 1% Nonidet P-40, 5mMEDTA, 5mMEGTA) supplemented
with Complete protease inhibitor cocktail (Roche Diagnostics). For in vivo
detection of ubiquitin conjugates, 10 μMMG132, 50 ng/ml Ub-aldehyde
and 2 mM NEM were added to the lysis buffer. Protein extract (50 μg)
was separated by 12% SDS–PAGE, blotted onto a nitrocellulosemembrane
and detected with speciﬁc antibodies. The immunoreactive bands were
detected by ECL (GE Healthcare) and imaged with a ChemiDoc XRS sys-
tem (Bio-Rad Laboratories). Densitometric analysis was performed
using the ImageLab 4.1 Software (Bio-Rad Laboratories).
Steady-state ﬂuorescence measurements
Human recombinant frataxin precursor (aa 1-210) was expressed
and puriﬁed by GenScript Corp., NJ, USA. Steady-state ﬂuorescence
spectra were recorded at 20 °C using an ISS PC1 ﬂuorometer (Iss Inc,
Champain, IL, USA). The afﬁnity of frataxin for the ligands studied in
this paper was determined by monitoring the decrease in Trp ﬂuores-
cence upon the addition of thesemolecules to solutions. The concentra-
tion of the protein was 2 μM while the concentration of the ligands
varied from 0.5 to 25 μM. At the excitationwavelength of 280 nm, emis-
sion spectra were recorded between 290 and 440 nm, using a 4 × 4mm
path-length quartz ﬂuorescence microcuvette (Hellma GmbH & Co.,
Fig. 6.UCM promote frataxin accumulation in FRDA cells and rescue the aconitase defect. FRDA patients-derived lymphoblasts cell lines FRDA 798 (A) and FRDA 214 (B) or lymphoblasts
derived from the corresponding unaffected carrier siblings, FRDA 241 or FRDA 215, respectively, were cultured in the presence of 10 μM of the indicated UCM, or DMSO alone (contr) for
5 days. Total cell extracts were resolved on SDS–PAGE and analyzedwith anti-frataxin antibody, or anti-tubulin, as a loading control. The graphs represent the relative frataxin abundance
as quantiﬁed by densitometric analysis and normalized with tubulin levels. Data represent the mean± SEM from four different independent experiments. P-values were calculated with
Student's t-test and were statistically signiﬁcant (*P b 0.05; **P b 0.01) compared to non-treated conditions. Tub: tubulin; mat: mature frataxin. (C) Patients-derived lymphoblasts FRDA
214 were cultured with DMSO alone (contr) or in the presence of 10 μM of UCM108 for 5 days. The unaffected carrier siblings FRDA 215 lymphoblasts were cultured with DMSO alone.
Total aconitase activities weremeasured and normalized as described in theMethods section. Data represent themean± SEM from four different independent experiments. P-values was
calculated with Student's t-test and was statistically signiﬁcant (**P b 0.01) compared to non-treated condition.
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strument correction curve obtained with standard ﬂuorescent com-
pounds such as N-acetyl tryptophanamide (NATA). All measurements
were also corrected for the inner-ﬁlter effect. To simulate the absorption
of ligandmolecules at the excitation and the emissionwavelengths, two
cuvettes (2 mm optical length), containing a solution of ligands in
buffer, were placed along the excitation and emission pathways. The
ﬂuorescence of NATA was thus measured varying the concentration of
quencher and four correction curves (one for each ligands) were
obtained.
Data were then plotted as fractional loss of Trp ﬂuorescence (ΔF/F0)
versus ligand concentration. Experimental data were analyzed by non-
linear regression through a hyperbolic binding isotherm, using the
Kaleidagraph program (Synergy Software).Enzyme assays
For determinations of aconitases and citrate synthase activity, FRDA
lymphoblasts were washed twice with ice-cold Dulbecco's phosphate-
buffered saline (DPBS) and lysed in CelLytic M buffer (Sigma-Aldrich)
supplemented with Complete protease inhibitor cocktail EDTA-free
(Roche) and 2 mM trisodium citrate. Citrate was included to prevent
the inactivation of iron-sulfur cluster of aconitases. Total aconitase ac-
tivity was measured spectrophotometrically at 340 nm using the
BIOXYTECH Aconitase-340TM Assay (OxisResearchTM 21041). The
assay reactions, containing 150 μg of cell extract, were performed fol-
lowing the supplier's procedure, with the exception of temperature in-
cubation at 25 °C. Citrate synthase activity was assessed using 15 μg of
cell extract with the Citrate Synthase Assay Kit (Sigma-Aldrich CS0720).
98 A. Ruﬁni et al. / Neurobiology of Disease 75 (2015) 91–99The aconitase activities were normalized with respect to citrate syn-
thase ratios; 1 mU of enzymewas deﬁned as the amount of protein that
converted 1 nmol of NADP+ in 1 min at 25 °C.Frataxin modeling
The crystal structure of human frataxin (PDB code 1EKG) (Dhe-
Paganon et al., 2000) was used as the reference structure. NMR solu-
tion structures (PDB code 1LY7, 15 models) (Musco et al., 2000) were
aligned on the crystal structure using the program Combinatorial
Extension (Shindyalov and Bourne, 1998). All the experimental struc-
tures were modeled with the software package Gromacs v. 4.6.5 to
add missing atoms and to reﬁne the models. Side chains ﬂexibility
was investigatedwith the program reduce. The reﬁned crystal structure
was used to generate 1000 protein models with tCONCOORD (Seeliger
and de Groot, 2010).Frataxin binding site analysis
The experimentally determined models of frataxin were used to in-
vestigate the location of putative binding pockets on the solvent accessi-
ble surface of the protein using Metapocket (Huang, 2009), a freely
available server that includes eight different methods: ConCavity (Capra
et al., 2009), Fpocket (Le Guilloux et al., 2009), GHECOM (Kawabata,
2010), LIGSITE (Huang and Schroeder, 2006), PASS (Brady and Stouten,
2000), POCASA (Yu et al., 2010), Q-SiteFinder (Laurie and Jackson,
2005) and SURFNET (Laskowski, 1995). Mdpocket (Le Guilloux et al.,
2009) was employed to investigate transient pockets using the
computer-generated models obtained by tCONCOORD (Seeliger and
de Groot, 2010).Molecular docking
AutoDock (Morris et al., 2009) and AutoDock/Vina (Trott and Olson,
2010)were used to conduct virtual screening experiments. Screening of
large data sets was conducted with AutoDock/Vina using a rigid model
for the protein. Focused libraries weremodeled using AutoDock ﬂexible
approaches:ﬂexible docking inwhich selected side chains are treated as
ﬂexible; conformational selections experiments conducted on the
tCONCOORD-generatedmodels (Seeliger and deGroot, 2010)were per-
formed on selected ligands (UCM71 and UCM108).Cheminformatics and database searching
In-house database of commercially available compounds was
screened to search for compounds containing the sulfonyl-hydrazone
scaffold with aromatic substituents using the following criteria:
MW b 500, logP b 5, no atomswith undeﬁned stereo, no reactive groups
(Oprea, 2000). More than 5000 compounds were identiﬁed and docked
on the X-ray structure of frataxin. About 100 molecules were selected
and bought for biological testing. Bioisosters of sulfonyl-hydrazones
were modeled and screened with the docking procedures described
above.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2014.12.011.Acknowledgments
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